Buoyed by the Emergency Use Authorisation approval from the Drug Controller General of India (DCGI)for its Covid-19 vaccine Covaxin, Bharat Biotech has said Phase-1 clinical trials of its new intranasal antidote for the killer virus will begin during February-March this year.source https://timesofindia.indiatimes.com/india/bharat-biotech-to-begin-phase-1-trials-of-its-intranasal-vaccine-for-covid-19-in-feb-march/articleshow/80165865.cms
Comments
Post a Comment